Pfizer’s Troxyca And The Limits Of Advisory Committee Review For Opioids

FDA approved Pfizer’s oxycodone/naltrexone extended release opioid with abuse deterrent claims similar to Embeda. That isn’t the label FDA’s advisory committee supported.

FDA’s approval of Pfizer’s Troxyca (oxycodone/naltrexone) is a quiet milestone: the first new opioid formulation to clear the agency since FDA updated its policy regarding reviews of the products in light of the prescription drug abuse crisis.

Under FDA’s February opioid action plan, the agency committed to bring most new opioid panels to committee prior...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards